Embecta said its patch pump would require additions to be commercially competitive, and plans to use the funds saved to pay ...
Get up to 30% off detailed market research reports-for a limited time only! The insulin patch pumps market size is expected to see rapid growth in the next few years. It will grow to $2.16 billion ...
Jury finds medical device company misappropriated secrets covering Insulet’s Omnipod l Insulet “extremely pleased” with ...
Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.
The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create ...
Insulin pump maker Insulet won $452 million in its trade secret case against Korean rival EOFlow, the company announced on ...
Embecta (Nasdaq:EMBC) filed with the state of Massachusetts to confirm a workforce reduction affecting 118 employees.
CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the ...
A jury found that competitor EOFlow and former executives misappropriated trade secrets for Insulet’s Omnipod insulin pumps.
The Massachusetts district court awarded Insulet a total of $452 million, including $170 million in compensation plus $282 ...
Embecta Corp.'s Q4 results showed significant net income and EPS growth. Embecta also announced a restructuring plan. See why ...
Insulet Corp., a Massachusetts-based medical device company, secured a staggering $452 million jury verdict against South ...